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Animal studies suggest an important role for the metabotropic glutamate receptor subtype 5 
(mGlu5) in the pathophysiology of alcohol dependence, but direct human evidence is lacking. The 
goal of this study was to investigate cerebral mGlu5 availability in alcohol-dependent patients 
versus controls using 18F-FPEB positron emission tomography. Methods: Dynamic 90 minute 18F-
FPEB scans combined with arterial blood sampling were acquired in 16 recently abstinent alcohol-
dependent patients and 32 age-matched controls. Regional mGlu5 availability was quantified by 
the 18F-FPEB total distribution volume using both a voxel-by-voxel and a volume-of-interest 
analysis with partial-volume effect correction. Alcohol consumption within the last 3 months was 
assessed by questionnaires and by hair ethyl glucuronide analysis. Craving was assessed using the 
Desire for Alcohol Questionnaire. Results: mGlu5 availability was lower in mainly limbic regions 
of alcohol-dependent patients compared to controls (P<0.05, family-wise error corrected), ranging 
from 14% in the posterior cingulate cortex up to 36% in the caudate nucleus. Lower mGlu5 
availability was associated with higher hair ethyl glucuronide levels for most regions, and was 
related to a lower level of craving specifically in the middle frontal gyrus, cingulate cortex and 
inferolateral temporal lobe. Conclusion: These findings provide first human in vivo evidence for a 
role of limbic mGlu5 in the pathophysiology of alcohol dependence, possibly involved in a 
compensatory mechanism helping to reduce craving during abstinence.  
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In 2009, Peter W. Kalivas proposed ‘the glutamate homeostasis hypothesis of addiction’. 
According to it, the transition from controlled drug use to dependence involves long-lasting 
glutamatergic neuroadaptations in corticolimbic areas (1). Among others, impaired mGlu5-
dependent signaling is hypothesized to represent a key component of these adaptations. The mGlu5 
is a widely distributed G11/q-protein coupled receptor of the human brain, with highest expression 
in corticolimbic areas (2). Mainly located on post-synaptic terminals, mGlu5 is integral to synaptic 
plasticity processes partly via its functional positive coupling with the N-methyl-D-aspartate 
receptor (3). Kalivas’s theory posit that chronic drug administration results in a mGlu5 
downregulation, representing a compensatory adaptation helping to reduce compulsive drug-
seeking. Hence, mGlu5 has been proposed as a promising target for the treatment of several types 
of substance dependence (4).  
Alcohol dependence is a major health concern associated with high societal costs worldwide (5), 
and with high relapse rates despite available therapies. Therefore, understanding the neural 
mechanisms that mediate the transition from controlled use to dependence in humans remains a 
priority of alcohol research.  
To date, few preclinical studies investigated the effect of chronic alcohol administration on mGlu5 
density, revealing either a mGlu5 hypo-expression in the hippocampus (6), an over-expression in 
the amygdala (7), or no alterations (8) or over-expression (9) in the ventral striatum. In contrast, 
extensive research showed that blocking mGlu5 signaling by genetic or pharmacological 
interventions reduces alcohol rewarding properties (10-14) as well as the severity of withdrawal 
and relapse behaviors following alcohol deprivation in rodents (13,15-19).  
In the last 10 years, the highly selective and potent mGlu5 positron emission tomography (PET) 
radioligand 18F-FPEB has allowed quantification of mGlu5 availability (20), thereby providing a 
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unique opportunity to examine how mGlu5 may adapt across the different stages of alcohol 
dependence. Noteworthy, 18F-FPEB PET has shown that limbic mGlu5 positively relates to 
novelty-seeking (21), a heritable temperament trait associated with increased susceptibility to drug 
dependence (22). Moreover, genetic studies have demonstrated that individuals with specific 
mGlu5 polymorphisms are at higher risk for developing alcohol dependence (23,24). However, the 
in vivo status of mGlu5 availability in alcohol-dependent patients and its possible relation to clinical 
outcome is unknown.  
Here, we investigated mGlu5 availability in recently abstinent alcohol-dependent patients 
compared to controls using 18F-FPEB PET. Considering the largely shared neurobehavioral deficits 
observed among various types of drug dependences (25) and the known hyperglutamatergic state 
associated with alcohol withdrawal (26), we hypothesized that short-term alcohol abstinence would 
also be associated with lower cerebral mGlu5 availability. Additionally, we addressed whether a 
potential lower mGlu5 availability in alcohol-dependent patients is related to the amount of prior 
alcohol consumption and to craving. 
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MATERIALS AND METHODS 
Participants 
Patients with a DSM-IV diagnosis of alcohol dependence were recruited by a board-
certified psychiatrist specialized in addiction at the Psychiatric Hospital Alexianen Tienen and the 
Psychiatry Department of the University Hospital Leuven (Belgium). All patients were included 
within the first 2 weeks of supervised abstinence. Exclusion criteria were any of the following: 
other psychiatric diseases (including first-degree relative), substance use disorders except nicotine 
dependence, chronic use of benzodiazepines, and abnormal findings on physical examination, 
blood test (with a tolerance for liver tests of ≤2 times the limit value), urine toxicology (Multi Urine 
Drugcontrol cassette, Ultimed Products, Germany) or structural magnetic resonance imaging. 
According to the local clinical procedure, 6 patients temporarily received clorazepate (mean 
cumulative dose, 100 mg; range, 50-225 mg) to relieve withdrawal symptoms.  
Healthy controls were recruited through local advertisement and underwent a full medical and 
mental assessment at study intake. This sample represents a subsample of a previous study (27) 
and was randomly selected based on age by a person blind to both study protocols in order to obtain 
two age-matched controls for each patient (Table 1). Subjects reporting alcohol consumption >7 
units/week (one unit=10 g alcohol) or regular binge drinking (≥5 units/occasion) were excluded. 
Temperament traits were assessed using the 240-item Cloninger Temperament and Character 
inventory (28). 
The study protocol was approved by the Ethics Committee of the University Hospital Leuven. All 
participants signed a written informed consent 
 
Assessment of Alcohol Use and Craving 
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Alcohol consumption in the prior 3 months was determined subjectively by the Time-Line 
Follow Back method (29). Excessive alcohol use was further assessed using the Alcohol Use 
Disorders Identification Test (AUDIT) (30). Moreover, quantitative analysis of alcohol 
consumption was performed via hair ethyl glucuronide (hEtG) analysis (31), providing a 
quantitative measure of alcohol consumption over the prior 3 months (32).  
Alcohol craving in recently abstinent patients was assessed at the time of PET using the 13-item 
Dutch version of the Desire for Drugs Questionnaire (DDQ) adapted to alcohol (33). 
 
mGlu5 PET Imaging and Radiometabolites Analysis 
All subjects were asked to fast for 3 hours. Lack of alcohol consumption in the prior hours 
was verified by measuring breath alcohol concentration using a hand-held electronic device 
(Dräger Alcotest 6820, Luebeck, Germany). The radiometabolite analysis procedure has been 
described in detailed previously (20).  
18F-FPEB PET data were dynamically acquired on a HiRez Biograph PET/CT camera (Siemens 
Inc, Erlangen, Germany) for 90 min following bolus injection of 18F-FPEB (Table 1). PET data 
were analyzed using PMOD (v3.605, PMOD Technologies, Zurich, Switzerland) and statistical 
parametric mapping (SPM v12). The 18F-FPEB total distribution volume (VT, as defined by Innis 
et al. (34)) was used as a surrogate for mGlu5 availability. To obtain VT map, the Logan graphical 
approach (35) was used. For SPM analysis, VT images were spatially normalized to the Montreal 
Neurological Institute space. Additionally, voxel-based findings were corroborated with a 
volumes-of-interest (VOIs) analysis using the N30R83 Hammers probabilistic atlas (36). VOI-
based VT values were derived from a reversible two-tissue compartment model (20,37). To control 
for the confounding effect of potential brain atrophy, voxel-based and VOI-based PET data were 
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corrected for partial volume effects using Muller-Gartner (38) and Geometric Transfer Matrix (39) 
methods, respectively. 
 
Structural Magnetic Resonance Imaging and Brain Atrophy Assessment  
A structural brain magnetic resonance imaging was acquired on a 3-Tesla scanner (Philips 
Ingenia, Healthcare, The Netherlands) for automatic VOI determination and co-registration with 
PET images. Additionally, potential brain atrophy in patients was assessed both at the voxel level 




Based on previous studies (23,24), the genotype for mGlu5 polymorphisms rs3462, 
rs3824927, rs308787, rs11020526, rs7931721 and rs495695 was determined in all participants 
(Supplemental Materials).  
 
Statistical Analysis  
Conventional statistical analyses were performed using Statistica v12 (Statsoft, Tusla, 
Oklahoma). Normally distributed variables are reported as mean±standard deviation and skewed 
variables as median (interquartile range). Independent samples t-test or Mann-Whitney U test were 
used, as appropriate. Based on the suggested involvement of mGlu5 in normal aging (40) (27), age 
was included as covariate in all analyses.  
A SPM group comparison analysis was performed with smoking status as nuisance variable. VT 
images corrected for partial volume effects were smoothed using a Gaussian kernel of 12 mm. The 
statistical threshold was set at P<0.05, corrected for family-wise error (PFWE). To minimize the 
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chance of type I error in the secondary VOI-based analysis, only VOIs corresponding to regions 
with significant PFWE were considered. VOI-based group comparison were analyzed using a 
multivariate general linear model with 18F-FPEB VT values as dependent variables and group 
status, smoking status and age as independent predictors. The effect of mGlu5 polymorphisms, 
withdrawal treatment and abstinence period were tested by adding genotyping data, the received 
benzodiazepine dose and days of abstinence into the model, respectively. 
In patients, associations between VOI-based mGlu5 availability and self-reported alcohol use, 
hEtG levels and craving measurements were assessed using partial correlation coefficients with 
age as nuisance variable since both mGlu5 density (27) and alcohol craving (41) may be influenced 
by age.   





Participant characteristics are reported in Table 1. The two groups differed only for alcohol 
and nicotine use and the temperament trait harm avoidance. 
 
Brain Atrophy in Patients 
Compared to controls, voxel-based morphometry revealed lower gray matter volume in 
alcohol-dependent patients in the orbitofrontal cortex, straight gyrus, inferior/middle/superior 
temporal lobe, hippocampus, insula and putamen bilaterally (Fig. 1A). Consistently, evidence of 
brain atrophy in patients was observed in the additional VOI-based analysis (Fig. 1B). 
 
Group Differences in mGlu5 Availability  
All scans were performed at least 2 days from the last alcohol consumption (mean time 
interval, 7 d; range, 2-14 d) and at more than 24 h from the last clorazepate dosing (mean time 
interval, 91 h; range 25-186 h). 
After correction for partial volume effects and controlling for age and smoking status, SPM showed 
a significant lower mGlu5 availability in alcohol-dependent patients in various, mostly limbic, 
cortical and subcortical brain areas (Fig. 2, Supplemental Table 1). These findings were confirmed 
by the VOI analysis, detecting a lower mGlu5 availability in alcohol-dependent subjects ranging 
from 14% (posterior cingulate cortex) up to 36 % (caudate nucleus) (Fig. 3). Noteworthy, no 
significant 18F-FPEB VT differences were observed between smokers and non-smokers in alcohol-
dependent subjects in any region (global VT=22±4 in smokers and 19±2 in non-smokers; P=0.8). 
Finally, similar highly significant 18F-FPEB VT differences were observed using data uncorrected 
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for partial volume effects, supporting that group differences in brain volumes did not affect the 
present PET findings. No significant sex differences in mGlu5 availability were observed, conform 
to previous studies (27,42). Regarding mGlu5 polymorphisms, we found no significant effects of 
an individual polymorphism genotype on 18F-FPEB VT in either the control or the patient group.  
 
Correlation Between mGlu5 Availability and Alcohol Consumption  
In alcohol-dependent patient, mGlu5 availability in the thalamus, insula, superior frontal 
gyrus, superior temporal gyrus and inferolateral temporal lobe was negatively correlated with hEtG 
concentration (Table 2, Fig. 4A). Concordant findings were observed at the voxel level using 
multiple regression analysis, except for the thalamus (P<0.001; Fig. 5). In contrast, no associations 
were found between mGlu5 and the self-reported alcohol consumption assessments. Additionally, 
no associations between mGlu5 availability and the duration of alcohol consumption or the time of 
abstinence were observed. 
 
Correlation Between mGlu5 Availability and Alcohol Craving 
Using age as nuisance variable, VOI-based mGlu5 availability in patients correlated 
positively with the craving item ‘negative reinforcement’ in the cingulate cortex, middle frontal 
gyrus and inferolateral parietal lobe (Table 2, Fig. 4B-E). These results did not survive a Bonferroni 
correction for multiple testing and were not reproduced by SPM analysis, which may be due to the 
low effect size and the reduced sensitivity of the SPM compared to the VOI-based analysis, 
respectively.   




To our knowledge, this is the first study investigating mGlu5 availability in alcohol-
dependent patients in vivo. Within 2 weeks of supervised abstinence, alcohol-dependent patients 
demonstrated lower mGlu5 availability in mainly limbic areas. Moreover, mGlu5 availability was 
inversely correlated with the quantitative measure of recent alcohol consumption. Finally, we found 
a positive relationship between mGlu5 and alcohol craving during early abstinence, supporting the 
clinical significance of the present findings. 
In patients, we observed reduced mGlu5 availability in corticolimbic regions in which long-
lasting neuroadaptations are suggested to occur upon extensive alcohol exposure (1,26). A lower 
cerebral mGlu5 availability was also observed in nicotine- (43) and cocaine-dependent (44) 
patients, supporting the hypothesis that mGlu5 downregulation represents a common 
neuroadaptation occuring across various types of substance dependence. In alcohol dependence, a 
well-described neuroadaptation is the up-regulation of N-methyl-D-aspartate receptor expression 
and function, which contributes to the hyperglutamatergic state associated with short-term 
abstinence (45) and in turn, to neurotoxicity (46), anxiety (47), craving (48) and relapse (49). 
Therefore, given the functional positive coupling of mGlu5 and N-methyl-D-aspartate receptor (3), 
mGlu5 availability might serve as a compensatory mechanism to attenuate this hyperglutamatergic 
state by reducing postsynaptic excitability. On the other hand, given its critical role in adaptive 
learning (50), impaired mGlu5-dependent plasticity may contribute to the chronic inability of 
dependent individuals to extinguish drug-associated memories and to form adaptive behaviors to 
escape drug seeking and taking (51,52).  
In patients, the finding of a negative association between hEtG concentrations and mGlu5 
suggests a dose-response relationship to alcohol exposure. In contrast, no significant associations 
by KU Leuven University Library on January 22, 2018. For personal use only. jnm.snmjournals.org Downloaded from 
13 
 
were found with self-reported alcohol measures. This discrepancy might be due to the difficulty in 
recalling accurate amounts of consumed alcohol in presence of cognitive impairments and/or due 
to the well-known tendency to underestimate or inaccurately report one’s own alcohol use (53).  
An important consideration to address is whether the present findings have some clinical 
implications. A fundamental component of alcohol dependence is craving. Using a subjective 
assessment of craving (54), we found a positive relationship between the craving dimension 
‘negative reinforcement’ and mGlu5 availability in specific regions that are involved in controlling 
drug craving (55,56). This association between mGlu5 and craving is also in line with preclinical 
evidence showing that antagonism of mGlu5 reduces the escalation of alcohol use as well as 
anxiety-like (57) and relapse-like behaviors (58). Therefore, our findings support the potential of 
specific mGlu5 negative modulators to reduce craving and relapse in alcohol-dependent patients 
(59).  
Some limitations of this study need to be mentioned. First, the sample size of alcohol-
dependent patients was small, though large enough to draw robust conclusions regarding group 
difference in mGlu5 availability. In contrast, the correlations with craving showed small effect size 
and this finding should be seen as preliminary. Second, considering the hyperglutamatergic state 
associated with alcohol withdrawal (26), group differences in extracellular glutamate levels 
potentially confound findings. Indeed, although binding to an allosteric site, radioligand 
displacement by endogenous glutamate might occur by other mechanisms than direct competition 
(60). Yet, we previously found no association between ACC 18F-FPEB VT and glutamate levels, 
supporting no major effects of endogenous glutamate on 18F-FPEB binding. Third, this study 
cannot disentangle whether the reduced mGlu5 availability in patients represents a pre-existent 
condition or a consequence of chronic alcohol use, which would be better investigated in 
longitudinal studies. Finally, mGlu5 scans have been performed within a rather large withdraw 
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time window (2-14 d). In view of the preclinical literature suggesting that mGlu5 expression varies 
depending on the time of abstinence and also the brain regions being studied (6-9), more studies 




In conclusion, we found that alcohol-dependent patients have lower corticolimbic mGlu5 
availability compared to controls. In specific regions, this reduction correlated negatively with the 
amount of recent alcohol consumed and positively with the negative reinforcement dimension of 
craving. These findings provide the first in vivo human evidence for a central role of mGlu5 in the 
neuroadaptations underlying alcohol dependence and support the potential of mGlu5 antagonists 
for the prevention or reduction of craving in patients. Future follow-up mGlu5 PET studies in the 
course of alcohol detoxification are warranted to assess both the potential reversibility of lower 
mGlu5 availability and the potential of mGlu5 PET for individual prediction of relapse. 
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Figure 1. Lower gray matter volumes in alcohol-dependent patients compared to controls. (A) 
Statistical parametric mapping displayed at P<0.001 (KEXT>50 voxels). (B) Volume-of-interest 
analysis.*P<0.05; **P<0.001. 
  




Figure 2. Lower mGlu5 availability (18F-FPEB VT) in alcohol-dependent subjects versus controls. 
Statistical parametric mapping displayed at PFWE<0.05 (KEXT>200 voxels).  
  




Figure 3. Volume-of-interest analysis of mGlu5 availability (18F-FPEB VT) in controls (black bars) 
versus alcohol-dependent subjects (gray bars). Bars and error bars are mean and standard deviation, 
respectively. CN, caudate nucleus; THA, thalamus; INS, insula; ACC, anterior cingulate cortex; 
PCC, posterior cingulate cortex; MID FR G, middle frontal gyrus; SUP FR G, superior frontal 
gyrus; SUP TEMP G (post), superior temporal gyrus, posterior part; SUP PAR G, superior parietal 
gyrus; PAR (inferolat), parietal lobe, inferolateral part. *P<0.05; **P<0.01; ***P<0.001. 
  




Figure 4. Alcohol-dependent subjects’ scatterplots showing the relation (A) between mGlu5 
availability (18F-FPEB VT) and hair ethyl glucuronide (hEtG) levels at a mean composite VOI, and 
(B, C, D and E) between mGlu5 availability and the negative reinforcement craving score for the 
anterior cingulate (ACC), posterior cingulate (PCC), middle frontal gyrus (MID FR G) and 
inferolateral temporal lobe.  
   




Figure 5. Statistical parametric mapping showing the negative association between mGlu5 
availability (18F-FPEB VT) and hair ethyl glucuronide (hEtG) levels in alcohol-dependent patients 
(P<0.001, KEXT>50 voxels).  
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Gender (female/male) 3/13 14/18 0.088 
Age (years) 46±8 45±13 0.80 
Body mass index (kg/m 2) 24.8±3.5 24.5±3.5 0.70 
Education (years) 15.5±5.7 16.1±4.4 0.67 
Temperament traits (TCI scores)    
   Novelty-seeking 19.1±6.7 16.2±4.8 0.093 
   Harm avoidance 20.6±9.2 13.3±5.6 0.001 
   Reward dependence 15.8±4.7 17.5±4.2 0.22 
   Persistence 4.7±2.4 4.9±2.1 0.85 
Family history of alcoholism (yes/no) 13/3 0/32 <0.001 
Alcohol use     
   Reported intake (grams/week) 1627±648 24±21 <0.001 
   Hair ethyl glucuronide level (pg/mg) 221.5 (375.1) 8.1 (12.2) <0.001 
   AUDIT score 27±4 2±1 <0.001 
   Reported use (years) 26.5±12.9 26.6±8.1 0.99 
   Reported problematic use (years) 12.7±10.7 - - 
   Abstinence (days) 7.3±4.0 - - 
Alcohol craving (DDQ scores)     
   Desire and intention 15.7±7.0 - - 
   Negative reinforcement 14.8±6.5 - - 
   Control 4.0 (5.0) - - 
Nicotine use    
   Yes/no 11/5 0/32 <0.001 
   Number of cigarettes per day 18.5 (20) - - 
   Regular use (years) 23±6 - - 
   FTND score 5.5±2.7 - - 
18F-FPEB    
   Injected activity (MBq) 175±11 177.0±7 >0.5 
   Specific activity (MBq/nmol) 97±51 90±52 >0.5 
   Injected mass (µg) 0.6±0.4 0.6±0.6 >0.5 
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AUDIT=Alcohol Use Disorder Identification Test; DDQ=Desire for Drug Questionnaire adapted 
for alcohol; FTND=Fagerstrom Test for Nicotine Dependence. Continuous data are mean±standard 
deviation or median (interquartile range) and dichotomous data are numbers.  
by KU Leuven University Library on January 22, 2018. For personal use only. jnm.snmjournals.org Downloaded from 
29 
 
Table 2. Partial correlation coefficients* of mGluR5 availability (18F-FPEB VT) versus recent 
alcohol consumption and craving in alcohol-dependent subjects.  
 
Volume-of-interest 
hEtG levels  
(pg/mg) 





r P r P r P r P 
Caudate Nucleus -0.38 0.20 0.05 0.86 0.10 0.73 -0.15 0.58 
Thalamus -0.65 0.03 0.00 1.00 0.48 0.07 0.16 0.57 
Insula -0.58 0.04 -0.21 0.46 0.49 0.06 0.24 0.40 
Anterior Cingulate Cortex -0.43 0.04 -0.14 0.61 0.52 0.05 0.26 0.36 
Posterior Cingulate Cortex -0.45 0.12 0.04 0.88 0.57 0.03 0.18 0.51 
MID FR G -0.50 0.08 -0.10 0.73 0.59 0.02 0.18 0.52 
SUP FR G -0.57 0.04 -0.08 0.78 0.50 0.06 0.08 0.77 
SUP TEMP G (post) -0.58 0.04 -0.18 0.52 0.43 0.11 0.02 0.95 
SUP PAR G -0.56 0.04 -0.03 0.91 0.50 0.06 0.09 0.76 
PAR (inferolat) -0.52 0.06 -0.02 0.95 0.53 0.04 0.05 0.85 
Mean (n=10 VOIs) -0.56 0.04 -0.09 0.76 0.53 0.04 0.11 0.69 
 
* with age as nuisance variable. 
DDQ=Desire for Drug Questionnaire adapted for alcohol; hEtG=Hair Ethyl Glucuronide; MID FR 
G=middle frontal gyrus; SUP FR G=superior frontal gyrus; SUP TEMP G (post)=superior 
temporal gyrus, posterior part; SUP PAR G=superior parietal gyrus; PAR (inferolat)=parietal lobe, 
inferolateral part. 
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